Table 1.
Time-course study of echocardiography in WT and Nrf2−/− mice after Dox treatment.
| WT | Nrf2−/− | |||
|---|---|---|---|---|
| (n) Vehicle (3) | Dox (5) |
Vehicle (3) | Dox (5) | |
| Day 0 | ||||
| LVPW; d (mm) | 0.69 ± 0.02 | 0.65 ± 0.05 | 0.67 ± 0.04 | 0.68 ± 0.03 |
| LVPW; s (mm) | 1.05 ± 0.02 | 1.05 ± 0.05 | 0.98 ± 0.04 | 0.98 ± 0.03 |
| FS (%) | 28.90 ± 1.56 | 28.31 ± 3.97 | 29.50 ± 2.00 | 28.53 ± 1.19 |
| LV Vol; d (µL) | 60.41 ± 0.02 | 60.86 ± 0.01 | 61.56 ± 0.07 | 60.53 ± 0.02 |
| LV Vol; s (µL) | 23.68 ± 0.04 | 23.78 ± 0.01 | 24.08 ± 0.07 | 23.81 ± 0.03 |
| HR | 469.27 ± 52.42 | 423.62 ± 29.97 | 438.00 ± 38.73 | 426.70 ± 50.89 |
| Day 1 | ||||
| LVPW; d (mm) | 0.69 ± 0.03 | 0.68 ± 0.02 | 0.66 ± 0.01 | 0.65 ± 0.03 |
| LVPW; s (mm) | 1.07 ± 0.03 | 1.01 ± 0.02 | 0.99 ± 0.01 | 0.90 ± 0.03B;C |
| FS (%) | 31.12 ± 2.90 | 28.23 ± 1.10 | 31.03 ± 2.00 | 20.98 ± 1.94B;C |
| LV Vol; d (µL) | 61.78 ± 0.09 | 61.92 ± 0.03 | 63.02 ± 0.01 | 60.45 ± 0.02 |
| LV Vol; s (µL) | 24.40 ± 0.08 | 24.10 ± 0.03 | 24.92 ± 0.07 | 22.91 ± 0.03 |
| HR | 442.06 ± 16.11 | 429.90 ± 20.29 | 439.22 ± 11.07 | 431.73 ± 32.97 |
| Day 2 | ||||
| LVPW; d (mm) | 0.71 ± 0.09 | 0.67 ± 0.05 | 0.69 ± 0.06 | 0.60 ± 0.02 |
| LVPW; s (mm) | 1.07 ± 0.09 | 0.97 ± 0.05 A | 0.97 ± 0.06 | 0.83 ± 0.02B;C |
| FS (%) | 28.03 ± 1.05 | 23.00 ± 3.37A | 30.29 ± 6.02 | 17.89 ± 3.16B;C |
| LV Vol; d (µL) | 62.47 ± 0.04 | 60.82 ± 0.01 | 60.92 ± 0.02 | 58.73 ± 0.07B;C |
| LV Vol; s (µL) | 25.80 ± 0.03 | 24.01 ± 0.02 | 24.35 ± 0.02 | 20.99 ± 0.02B;C |
| HR | 451.67 ± 26.50 | 445.38 ± 20.20 | 452.44 ± 28.66 | 444.73 ± 20.33 |
| Day 4 | ||||
| LVPW; d (mm) | 0.70 ± 0.06 | 0.67 ± 0.02 | 0.66 ± 0.01 | 0.59 ± 0.03B;C |
| LVPW; s (mm) | 1.08 ± 0.06 | 0.96 ± 0.02A | 0.97 ± 0.01 | 0.79 ± 0.03B;C |
| FS (%) | 28.60 ± 0.80 | 21.71 ± 3.40 A | 29.13 ± 1.40 | 18.49 ± 1.36B;C |
| LV Vol; d (µL) | 63.17 ± 0.04 | 58.88 ± 0.08A | 60.39 ± 0.03 | 57.51 ± 0.03B;C |
| LV Vol; s (µL) | 24.28 ± 0.01 | 20.21 ± 0.01A | 22.96 ± 0.02 | 19.34 ± 0.08B;C |
| HR | 444.06 ± 13.36 | 437.33 ± 29.66 | 443.89 ± 19.76 | 427.60 ± 29.83 |
Male 10–12 wk old littermates of WT and Nrf2−/− mice were treated with single intraperitoneal injection of 25 mg/kg Dox or vehicle (Veh) control for 4 days and cardiac function was monitored daily as indicated. LVPW; d: left ventricular posterior wall thickness diastolic; LVPW; s: left ventricular posterior wall thickness systolic; FS: fractional shortening; LV Vol; d: left ventricular volume; diastolic; LV Vol; s: left ventricular volume; systolic; HR: heart rate. Animal number for each group is indicated in the parentheses. A P < 0.05 versus WT Vehicle; B P < 0.05 versus Nrf2−/− Vehicle; C P < 0.05 versus WT DOX.